Literature DB >> 31132080

Aneugen Molecular Mechanism Assay: Proof-of-Concept With 27 Reference Chemicals.

Derek T Bernacki1, Steven M Bryce1, Jeffrey C Bemis1, Stephen D Dertinger1.   

Abstract

A tiered bioassay and data analysis scheme is described for elucidating the most common molecular targets responsible for chemical-induced in vitro aneugenicity: tubulin destabilization, tubulin stabilization, and inhibition of mitotic kinase(s). To evaluate this strategy, TK6 cells were first exposed to each of 27 presumed aneugens over a range of concentrations. After 4 and 24 h of treatment, γH2AX, p53, phospho-histone H3 (p-H3), and polyploidization biomarkers were evaluated using the MultiFlow DNA Damage Assay Kit. The assay identified 27 of 27 chemicals as genotoxic, with 25 exhibiting aneugenic signatures, 1 aneugenic and clastogenic, and 1 clastogenic. Subsequently, a newly described follow-up assay was employed to investigate the aneugenic agents' molecular targets. For these experiments, TK6 cells were exposed to each of 26 chemicals in the presence of 488 Taxol. After 4 h, cells were lysed and the liberated nuclei and mitotic chromosomes were stained with a nucleic acid dye and labeled with fluorescent antibodies against p-H3 and Ki-67. Flow cytometric analyses revealed that alterations to 488 Taxol-associated fluorescence were only observed with tubulin binders-increases in the case of tubulin stabilizers, decreases with destabilizers. Mitotic kinase inhibitors with known Aurora kinase B inhibiting activity were the only aneugens that dramatically decreased the ratio of p-H3-positive to Ki-67-positive nuclei. Unsupervised hierarchical clustering based on 488 Taxol fluorescence and p-H3: Ki-67 ratios clearly distinguished compounds with these disparate molecular mechanisms. Furthermore, a classification algorithm based on an artificial neural network was found to effectively predict molecular target, as leave-one-out cross-validation resulted in 25/26 agreement with a priori expectations. These results are encouraging, as they suggest that an adequate number of training set chemicals, in conjunction with a machine learning algorithm based on 488 Taxol, p-H3, and Ki-67 responses, can reliably elucidate the most commonly encountered aneugenic molecular targets.
© The Author(s) 2019. Published by Oxford University Press on behalf of the Society of Toxicology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Mitotic kinase inhibitors; TK6 cells; aneugen; flow cytometry; spindle poisons

Year:  2019        PMID: 31132080      PMCID: PMC6657583          DOI: 10.1093/toxsci/kfz123

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.849


  43 in total

1.  The aurora kinase A inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells.

Authors:  Vikas Sehdev; DunFa Peng; Mohammed Soutto; M Kay Washington; Frank Revetta; Jeffrey Ecsedy; Alexander Zaika; Tilman T Rau; Regine Schneider-Stock; Abbes Belkhiri; Wael El-Rifai
Journal:  Mol Cancer Ther       Date:  2012-02-01       Impact factor: 6.261

2.  Investigating the Generalizability of the MultiFlow ® DNA Damage Assay and Several Companion Machine Learning Models With a Set of 103 Diverse Test Chemicals.

Authors:  Steven M Bryce; Derek T Bernacki; Stephanie L Smith-Roe; Kristine L Witt; Jeffrey C Bemis; Stephen D Dertinger
Journal:  Toxicol Sci       Date:  2018-03-01       Impact factor: 4.849

3.  Noscapine hydrochloride disrupts the mitotic spindle in mammalian cells and induces aneuploidy as well as polyploidy in cultured human lymphocytes.

Authors:  M Schuler; P Muehlbauer; P Guzzie; D A Eastmond
Journal:  Mutagenesis       Date:  1999-01       Impact factor: 3.000

4.  Predictions of genotoxic potential, mode of action, molecular targets, and potency via a tiered multiflow® assay data analysis strategy.

Authors:  Stephen D Dertinger; Andrew R Kraynak; Ryan P Wheeldon; Derek T Bernacki; Steven M Bryce; Nikki Hall; Jeffrey C Bemis; Sheila M Galloway; Patricia A Escobar; George E Johnson
Journal:  Environ Mol Mutagen       Date:  2019-02-27       Impact factor: 3.216

5.  BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity.

Authors:  Dorothea Rudolph; Martin Steegmaier; Matthias Hoffmann; Matthias Grauert; Anke Baum; Jens Quant; Christian Haslinger; Pilar Garin-Chesa; Günther R Adolf
Journal:  Clin Cancer Res       Date:  2009-04-21       Impact factor: 12.531

6.  A class of 2,4-bisanilinopyrimidine Aurora A inhibitors with unusually high selectivity against Aurora B.

Authors:  Ignacio Aliagas-Martin; Dan Burdick; Laura Corson; Jennafer Dotson; Jason Drummond; Carter Fields; Oscar W Huang; Thomas Hunsaker; Tracy Kleinheinz; Elaine Krueger; Jun Liang; John Moffat; Gail Phillips; Rebecca Pulk; Thomas E Rawson; Mark Ultsch; Leslie Walker; Christian Wiesmann; Birong Zhang; Bing-Yan Zhu; Andrea G Cochran
Journal:  J Med Chem       Date:  2009-05-28       Impact factor: 7.446

7.  PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer.

Authors:  Patrizia Carpinelli; Roberta Ceruti; Maria Laura Giorgini; Paolo Cappella; Laura Gianellini; Valter Croci; Anna Degrassi; Gemma Texido; Maurizio Rocchetti; Paola Vianello; Luisa Rusconi; Paola Storici; Paola Zugnoni; Claudio Arrigoni; Chiara Soncini; Cristina Alli; Veronica Patton; Aurelio Marsiglio; Dario Ballinari; Enrico Pesenti; Daniele Fancelli; Jürgen Moll
Journal:  Mol Cancer Ther       Date:  2007-12       Impact factor: 6.261

8.  Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines.

Authors:  Marc Payton; Tammy L Bush; Grace Chung; Beth Ziegler; Patrick Eden; Patricia McElroy; Sandra Ross; Victor J Cee; Holly L Deak; Brian L Hodous; Hanh Nho Nguyen; Philip R Olivieri; Karina Romero; Laurie B Schenkel; Annette Bak; Mary Stanton; Isabelle Dussault; Vinod F Patel; Stephanie Geuns-Meyer; Robert Radinsky; Richard L Kendall
Journal:  Cancer Res       Date:  2010-10-08       Impact factor: 12.701

9.  VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo.

Authors:  Elizabeth A Harrington; David Bebbington; Jeff Moore; Richele K Rasmussen; Abi O Ajose-Adeogun; Tomoko Nakayama; Joanne A Graham; Cecile Demur; Thierry Hercend; Anita Diu-Hercend; Michael Su; Julian M C Golec; Karen M Miller
Journal:  Nat Med       Date:  2004-02-22       Impact factor: 53.440

10.  Genotoxicity of flubendazole and its metabolites in vitro and the impact of a new formulation on in vivo aneugenicity.

Authors:  David J Tweats; George E Johnson; Ivan Scandale; James Whitwell; Dean B Evans
Journal:  Mutagenesis       Date:  2015-10-06       Impact factor: 3.000

View more
  4 in total

1.  A somatic mutation-derived LncRNA signatures of genomic instability predicts the prognosis and tumor microenvironment immune characters in hepatocellular carcinoma.

Authors:  Chuan Jin; Jian-Sen Zhao; Xu-Qi Huang; Xian-Zi Yang; Feng Li; Ye Song; Fei-Yu Niu; Jin-Rong Lin; Lei Ma; Yan-Xia Shi; Xiao-Shan Li; Peng Jiang; Sha Gao
Journal:  Hepatol Int       Date:  2022-08-10       Impact factor: 9.029

2.  In vitro human cell-based aneugen molecular mechanism assay.

Authors:  Nikki E Hall; Kyle Tichenor; Steven M Bryce; Jeffrey C Bemis; Stephen D Dertinger
Journal:  Environ Mol Mutagen       Date:  2022-04-22       Impact factor: 3.579

3.  Kinetics of γH2AX and phospho-histone H3 following pulse treatment of TK6 cells provides insights into clastogenic activity.

Authors:  Steven M Bryce; Stephen D Dertinger; Jeffrey C Bemis
Journal:  Mutagenesis       Date:  2021-07-07       Impact factor: 2.954

4.  Evidence for an Aneugenic Mechanism of Action for Micronucleus Induction by Black Cohosh Extract.

Authors:  Derek T Bernacki; Steven M Bryce; Jeffrey C Bemis; Stephen D Dertinger; Kristine L Witt; Stephanie L Smith-Roe
Journal:  Environ Mol Mutagen       Date:  2019-10-30       Impact factor: 3.216

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.